title: Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.
authors.affiliation: Department of Biostatistics, University of Washington, Seattle, WA 98109, USA. pgilbert@scharp.org
authors.forename: Peter B
authors.initials: PB
authors.lastname: Gilbert
authors.forename: Li
authors.initials: L
authors.lastname: Qin
authors.forename: Steven G
authors.initials: SG
authors.lastname: Self
mesh_terms: D015415:Biomarkers; D001699:Biometry / Q000379:methods*; D003627:Data Interpretation, Statistical; D006801:Humans; D015233:Models, Statistical; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D014612:Vaccines / Q000494:pharmacology
chemical_list: D015415:Biomarkers; D014612:Vaccines